| 產品名稱 |
Rabies virus |
| 商品貨號 |
B195420 |
| Classification |
Rhabdoviridae, Lyssavirus |
| Agent |
Rabies virus |
| Strain |
CVS-27 |
| Biosafety Level |
2
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Product Format |
frozen 1 mL per vial |
| Storage Conditions |
-70°C or colder |
| Comments |
Deposited as a mouse brain preparation from Seligmann. Tissue culture adapted by Torres-Anjel in following lot. Challenge strain according to Division of Biological Standards and Quality Control. |
| Effect on Host |
No CPE produced on production host. |
| Recommended Host |
Neuro-2a (ATCC® CCL-131™) |
| Growth Conditions |
Temperature: 37°C
Recommendations for Infection: Plate cells 24-48 hours prior to infection and infect when cultures are 50% confluent. Remove medium and inoculate with a small volume of virus (e.g. 1 mL per 25 cm2) diluted to provide an optimal MOI (e.g. 0.1). Adsorb 1 hour at 37°C in a humidified 5% CO2 atmosphere, rocking every 20-30 minutes to redistribute inoculum. End adsorption by adding virus growth medium.
Incubation: 4 days |
| Name of Depositor |
EB Seligmann Jr., National Institutes of Health, MJ Torres-Anjel, University of Missouri |
| Source |
Derived from Pasteur strain |
| References |
Fernandes MV, et al. Mechanism of the cytopahic effect of Rabies virus in tissue culture. Virology 21: 128-131, 1963. PubMed: 14062905
Kissling RE. Growth of rabies virus in non-nervous tissue culture. Proc. Soc. Exp. Biol. Med. 98: 223-225, 1958. PubMed: 13554599
|
